<p>Leading researcher Dr. Deborah Donnell tells us why the HIV Prevention Trials Network (HPTN) changed the design of one of two trials testing long-acting cabotegravir, as an injectable PrEP. Deb Donnell is an expert statistician, one of the great minds behind trial design and one of the best teachers we know.</p>

Leading researcher Dr. Deborah Donnell tells us why the HIV Prevention Trials Network (HPTN) changed the design of one of two trials testing long-acting cabotegravir, as an injectable PrEP. Deb Donnell is an expert statistician, one of the great minds behind trial design and one of the best teachers we know.

S1 Ep2: Testing Long-Acting PrEP, Easier Said Than Done

<p>Px Pulse explores vital topics confronting the field of HIV prevention research. Our monthly podcast will deepen your knowledge and help you “check the pulse” of this fast-paced field and the urgent challenges still ahead. Tune in for interviews, first-person accounts and robust discussion from advocates, researchers, policy-makers and community stakeholders as they take on critical issues facing HIV prevention research today.</p>

Science

Health & Fitness

Education

Px Pulse explores vital topics confronting the field of HIV prevention research. Our monthly podcast will deepen your knowledge and help you “check the pulse” of this fast-paced field and the urgent challenges still ahead. Tune in for interviews, first-person accounts and robust discussion from advocates, researchers, policy-makers and community stakeholders as they take on critical issues facing HIV prevention research today.

Share S1 Ep2: Testing Long-Acting PrEP, Easier Said Than Done

Sign up to save your podcasts

S1 Ep2: Testing Long-Acting PrEP, Easier Said Than Done

S1 Ep2: Testing Long-Acting PrEP, Easier Said Than Done